Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.

OBJECTIVES: The impact of inhaled corticosteroids (ICS) on eosinophilic inflammation in asthma is well established, but their effect in a real-life setting has not been extensively studied. Our purpose was to investigate the effect of ICS on airway and systemic inflammation as well as on clinical outcomes in patients with asthma from clinical practice. DESIGN, SETTING AND PARTICIPANTS: We conducted a retrospective analysis on asthmatics from a secondary care centre in whom ICS were initiated/increased (n=101), stopped/decreased (n=60) or remained stable (n=63, used as a control group) between two visits with available sputum and blood cell counts.
RESULTS: The median time between both visits ranged from 1 to 2 years. Initiating or increasing ICS (median variation (IQR): 800 (400-1200) µg beclomethasone equivalent dose per day) reduced sputum eosinophils and fractional exhaled nitric oxide (P<0.0001) and to a lesser extent blood eosinophils (P<0.0001), while withdrawing or decreasing ICS (median variation (IQR): 900 (500-1200) µg beclomethasone equivalentdose per day) resulted in increased sputum eosinophils (P=0.008). No change was found in patients with a stable dose. The effectiveness of ICS in improving asthma control, quality of life, forced expiratory volume in 1 s (FEV1), bronchial hyper-responsiveness and exacerbation rate was only observed in the eosinophilic phenotype (sputum eosinophils ≥3%, n=79). In non-eosinophilic asthmatics, stepping-down ICS resulted in an improvement in asthma control and quality of life, without any significant change in FEV1 (n=38).
CONCLUSIONS: Our results confirm the effectiveness of ICS on eosinophilic inflammation in real life and demonstrate that their clinical benefit seems to be restricted to eosinophilic asthmatics. Our data also support a try for stepping-down ICS in non-eosinophilic asthmatics. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Our study population consisted of patients from real life.

We included a control group with patients not receiving inhaled corticosteroids (ICS) or keeping the same dose of ICS between two visits, in order to properly investigate the effects of an initiation/increased dose and cessation/decreased dose of ICS between two visits.

Our study was retrospective.

No formal sample size calculation was performed.

The cumulative dose of ICS received by the patients before the investigation was uncertain due to the variation in the delay between both visits and to the unknown adherence to treatment.

Introduction

Inhaled corticosteroids (ICS) are considered as the mainstay of asthma treatment. They have proved their ability to improve asthma control, quality of life, lung function and to reduce the rate of exacerbations in patients with asthma.1 Their effects are thought to be mediated by controlling airway inflammation and in particular by reducing the eosinophilic airway infiltration.2 Previous studies showed that an initiation of ICS reduced sputum eosinophils,3–7 while the reverse was observed with a withdrawal8 or a decrease of ICS.9 The effect of ICS on other sputum cell types, however, is more controversial.3 4 6 7 Likewise, whether ICS impact circulating leucocytes has been much less studied. Very few studies reported that ICS decreased blood eosinophils6 7 10 11 with no change in blood neutrophils,10 but their effect on other blood leucocytes still needs to be determined.

It is now recognised that asthma exhibits different airway inflammatory phenotypes.12 Pavord et al first showed that the initiation of budesonide 800 µg/day for 2 months improved asthma symptoms and reduced bronchial hyper-responsiveness to methacholine in patients with sputum eosinophils ≥3%, whereas no effect was observed in those with sputum eosinophils <3%.13 Other studies, with one of them based on a randomised, double-blind, placebo-controlled cross-over design,14 confirmed the importance of sputum eosinophils as a predictive marker of response to ICS,4 10 even if some authors reported a possible effect in non-eosinophilic asthmatics.15 16 Moreover, some studies with a limited number of subjects have shown that patients experiencing loss of asthma control after stepping-down ICS treatment were more likely to have eosinophilic asthma, while patients in whom this strategy might be acceptable were more often non-eosinophilic.9 17

We believe that it is important to validate findings from tightly regulated clinical trials in a real-life setting including a broad spectrum of patients with asthma who may not qualify for inclusion criteria in these trials.18 In this study, we took advantage of our large database of asthmatics seen in clinical practice to investigate the effect of ICS in real life on airway and systemic inflammation as well as on asthma control and lung function. We have selected 224 patients in whom ICS dose was initiated/increased (n=101), stopped/decreased (n=60) or remained stable (n=63) between two visits and in whom we had an analysed sputum and blood cell count for both these visits.

Methods

Study design, setting and participants

We conducted a retrospective study on patients with asthma recruited from the University Asthma Clinic of Liege (Belgium) between 1 May 2003 and 31 January 2017. The diagnosis of asthma was defined as the presence of typical symptoms (wheezing, breathlessness, chest tightness and cough) associated with the demonstration of an airflow variability (increase in forced expiratory volume in 1 s (FEV1) of at least 12% and 200 mL after inhalation of 400 µg salbutamol and/or a provocative concentration of methacholine causing a 20% fall in FEV1 (PC20M) <16 mg/mL. From our database, we selected patients who had at least two visits with a successful sputum and blood cell count and who were not treated with oral corticosteroids (OCS) at the time of the visit or during the 6 previous weeks. Those who were prescribed OCS during the visit because of an exacerbation were also excluded, as well as those treated with omalizumab and mepolizumab because these drugs may have confounding effects on sputum and blood cell counts. Three groups of patients were constituted: a first group of patients with an initiation/increased dose of ICS between two visits (n=101), a second group of patients with a cessation/decreased dose of ICS between two visits (n=60) and a third group of patients, used as a control group, with no ICS or a stable dose of ICS between two visits (n=63). For each patient, the delay between both visits was at least of 1 month.

Investigations conducted at the Asthma Clinic

Patients were classified as atopic if they had positive specific IgE (>0.35 kU/L) to at least one of the following aeroallergens: cat, dog, grass pollen, tree pollen, house dust mite and a mould mixture (Phadia, Groot-Bijgaarden, Belgium). Asthma control and quality of life were evaluated by the Juniper Asthma Control Questionnaire (ACQ)19 and mini-Asthma Quality of Life Questionnaire (mini-AQLQ),20 respectively. When patients’ visits were separated by at least 1 year, the number of severe exacerbations during the year prior to each visit was recorded. Severe exacerbations were defined as events requiring the use of systemic corticosteroids during at least 3 days.21 Spirometry was performed using a portable spirometer (Spirobank; MIR, Rome, Italy) connected to the computer software (Winspiro; MIR, Rome, Italy). Patients who had a FEV1 ≥70% predicted without any influence of bronchodilators underwent a methacholine challenge test to define the PC20M, as previously described.22 Fractional exhaled nitric oxide (FENO) was measured at a flow rate of 50 mL/s (NIOX; Aerocrine, Solna, Sweden). Sputum was induced and processed as previously described,23 with the whole expectorate technique. Patients were classified as eosinophilic or non-eosinophilic if they had a baseline sputum eosinophil count ≥ or <3%, respectively.24 The blood cell count and analysis of C reactive protein (CRP) and fibrinogen were performed by the routine laboratory of the University Hospital of Liege.

Statistical analysis

For categorical variables, the number of observations and percentage for each category were presented. For continuous variables compatible with a normal distribution, the mean and SD were used, while the median and IQR were preferred for continuous variables not compatible with a normal distribution. Comparisons between the three groups of patients were performed using a Pearson’s χ2 test for categorical variables, an analysis of variance for parametric continuous variables and a Kruskal-Wallis test for non-parametric continuous variables. Paired comparisons were performed between both visits of patients. The McNemar test was used to compare binary variables, the paired t test was used for continuous variables when the differences between both visits were compatible with a normal distribution and the Wilcoxon signed-rank test was preferred for continuous variables when the differences between both visits were not compatible with a normal distribution. For each tested variable, when the number of missing values exceeded 10%, the number of data taken into account in the statistical analysis was specified in the tables. For the group with an initiation/increased dose of ICS and the group with a cessation/decreased dose of ICS, we compared the changes in ACQ, mini-AQLQ, severe exacerbation rate and FEV1 between eosinophilic and non-eosinophilic asthmatics, using a Student’s t-test or a Mann-Whitney test. A P value <0.05 was considered statistically significant. We used STATA V.13.0 (Statistical Software, StataCorp LP) for the statistical analysis and GraphPad Prism V.7.03 (GraphPad Software, La Jolla, California, USA) for the figures.

Results

Subjects’ characteristics

Demographic characteristics of patients are given in table 1. The three groups were well matched regarding sex, age, body mass index, atopy, age of asthma onset and smoking status. The median time between two visits ranged from 1 to 2 years. The median increase in the ICS dose was 800 µg beclomethasone equivalent dose per day, while the median decrease was 900 µg beclomethasone equivalent dose per day.

Table 1

Subjects’ characteristics

	Patients with an initiation/increased dose of ICS between two visits	Patients with a cessation/decreased dose of ICS between two visits	Patients with no ICS or a stable dose of ICS between two visits	P value
n	101	60	63	–
Time between the two visits, years	1.0 (0.5–2.6)	1.5 (0.9–2.6)	2.0 (0.7–3.8)	0.045
Women, n (%)	56 (55)	33 (55)	41 (65)	0.41
Age, years	53 (40–63)	51 (37–62)	53 (44–66)	0.42
BMI, kg/m²	26.3±5.1	26.4±4.7	26.8±4.9	0.83
Atopy, n (%)	52 (51)	35 (58)	32 (51)	0.64
Age of asthma onset, years	41 (16–57)	31 (8–53)	46 (27–55)	0.12
Smoking status, n (%)				0.22
Non-smokers	53 (52)	31 (52)	32 (51)
Current smokers	11 (11)	11 (18)	15 (24)
Ex-smokers	37 (37)	18 (30)	16 (25)
Patients with EA at first visit, n (%)	79 (78)	22 (37)	26 (41)	<0.001
Variation of ICS dose*	800 (400–1200)	900 (500–1200)	0	–

*ICS dose expressed in beclomethasone chlorofluorocarbon (CFC) equivalents.

BMI, body mass index; EA, eosinophilic asthma; ICS, inhaled corticosteroid.

Effect of an initiation/increased dose of ICS between two visits

The effects of an initiation (n=44)/increased dose (n=57) of ICS between two visits in the whole cohort are shown in table 2. There was a significant improvement in asthma control, asthma quality of life and airway hyper-responsiveness to methacholine by more than one doubling dilution. Initiating or increasing the dose of ICS led to a highly significant decrease of 57% in FENO and 80% in absolute sputum eosinophils. There was also a slight but significant reduction in absolute blood eosinophils (19%), lymphocytes (8%) and basophils (12%).

Table 2

Comparison of clinical, treatment, sputum and blood characteristics before and after an initiation/increased dose of ICS

	Patients before an initiation/increased dose of ICS (N=101)	Patients after an initiation/increased dose of ICS (N=101)	P value
ACQ	2.1±1.2	1.7±1.3	0.003
Mini-AQLQ	4.6±1.4	4.9±1.5	0.0008
Number of severe exacerbations in the previous year*	0.6±0.2†	0.2±0.1†	0.10
Prebronchodilator FEV1, % predicted	79.1±18.9	81.7±19.8	0.08
PC20M, mg/mL	1.58 (0.30–3.82)‡	3.42 (0.93–>16)‡	0.001
ICS dose, beclomethasone equivalents	400 (0–800)	1000 (800–2000)	–
LABA, n (%)	51 (51)	91 (90)	<0.0001
LTRA, n (%)	21 (21)	24 (24)	0.65
Theophylline, n (%)	3 (3)	3 (3)	1.0
Antihistamine, n (%)	18 (18)	19 (19)	1.0
FENO, ppb	60 (24–98)§	26 (16–52)§	<0.0001
Sputum total non-squamous cell count, × 106/g	1.48 (0.66–3.56)	1.46 (0.72–3.09)	0.81
Sputum viability, %	72 (54–84)	68 (55–82)	0.67
Sputum squamous cells, %	13 (5–24)	14 (5–28)	0.22
Sputum eosinophils
× 103/g	221 (43–696)	45 (7–266)	<0.0001
% of non-squamous cells	13.2 (3.8–36.0)	3.8 (0.4–15.4)	<0.0001
Sputum neutrophils
× 103/g	460 (171–1352)	744 (286–1697)	0.13
% of non-squamous cells	38.6 (20.2–64.4)	59.8 (37.6–79.4)	<0.0001
Sputum macrophages
× 103/g	302 (99–957)	253 (98–642)	0.40
% of non-squamous cells	22.8 (9.6–34.8)	18.8 (8.8–31.8)	0.22
Sputum lymphocytes
× 103/g	21 (2–52)	13 (2–39)	0.21
% of non-squamous cells	1.2 (0.4–2.4)	1.2 (0.2–2.5)	0.83
Sputum epithelial cells
× 103/g	41 (14–152)	37 (8–119)	0.73
% of non-squamous cells	3.4 (1.4–6.8)	2.6 (1.0–7.6)	0.57
Blood leucocytes, × 109/L	7.66 (6.47–8.77)	7.59 (6.47–9.04)	0.37
Blood eosinophils
/µL	272 (185–509)	221 (122–413)	<0.0001
%	3.8 (2.3–5.7)	2.9 (1.6–5.6)	<0.0001
Blood neutrophils
/µL	3976 (3201–4895)	4098 (3466–5344)	0.25
%	53.4 (46.6–58.8)	54.8 (50.4–62.4)	0.0007
Blood monocytes
/µL	513 (385–668)	559 (414–692)	0.22
%	6.5 (5.3–8.2)	7.1 (5.7–8.6)	0.046
Blood lymphocytes
/µL	2527(2083–2926)	2329 (1771–2900)	0.021
%	33.2 (26.6–38.0)	31.3 (26.1–36.9)	0.061
Blood basophils
/µL	43 (25–63)	38 (22–50)	0.016
%	0.5 (0.4–0.7)	0.4 (0.3–0.6)	0.026
CRP, mg/L	1.9 (0.7–3.9)¶	1.5 (0.8–4.3)¶	0.66
Fibrinogen, g/L	3.3 (2.8–3.7)**	3.3 (2.8–3.6)**	0.83

*Data are presented as mean±SEM.

Data available for both visits in: †35, ‡27, 91, ¶69 and **64 patients.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts per billion.

Effect of a cessation/decreased dose of ICS between two visits

In the whole cohort (table 3), withdrawing (n=18) or decreasing (n=42) the dose of ICS led to a significant selective threefold increase in absolute sputum eosinophils and a slight decrease in absolute blood neutrophils (13%).

Table 3

Comparison of clinical, treatment, sputum and blood characteristics before and after a cessation/decreased dose of ICS

	Patients before a cessation/decreased dose of ICS (N=60)	Patients after a cessation/decreased dose of ICS (N=60)	P value
ACQ	2.0±1.3	1.8±1.2	0.19
Mini-AQLQ	4.3±1.5	4.6±1.5	0.066
Number of severe exacerbations in the previous year*	0.7±0.3†	0.2±0.1†	0.009
Prebronchodilator FEV1, % predicted	79.0±17.8	78.0±20.0	0.54
PC20M, mg/mL	16.00 (4.17->16)‡	3.68 (1.52->16)‡	0.069
ICS dose, beclomethasone equivalents	1600 (900–2100)	450 (0–1100)	–
LABA, n (%)	50 (83)	42 (70)	0.057
LTRA, n (%)	18 (30)	16 (27)	0.63
Theophylline, n (%)	1 (2)	1 (2)	1.0
Antihistamine, n (%)	11 (18)	16 (27)	0.13
FENO, ppb	18 (12–48)§	23 (13–47)§	0.63
Sputum total non-squamous cell count, × 106/g	1.18 (0.53–3.51)	1.21 (0.65–2.67)	0.99
Sputum viability, %	70 (63–81)	68 (58–80)	0.54
Sputum squamous cells, %	16 (4–29)	14 (3–28)	0.52
Sputum eosinophils
× 103/g	14 (1–120)	44 (5–239)	0.008
% of non-squamous cells	1.9 (0.2–6.9)	2.8 (0.7–15.5)	0.016
Sputum neutrophils
× 103/g	535 (146–1770)	854 (242–1469)	0.64
% of non-squamous cells	48.9 (25.4–77.8)	61.0 (36.6–78.6)	0.13
Sputum macrophages
× 103/g	353 (115–744)	247 (113–696)	0.39
% of non-squamous cells	28.6 (11.2–54.9)	19.0 (11.3–34.7)	0.006
Sputum lymphocytes
× 103/g	11 (2–50)	13 (6–56)	0.09
% of non-squamous cells	1.2 (0.4–2.1)	1.4 (0.6–2.8)	0.19
Sputum epithelial cells
× 103/g	53 (7–141)	49 (16–127)	0.91
% of non-squamous cells	3.5 (1.0–9.9)	4.9 (1.6–8.9)	0.53
Blood leucocytes, × 109/L	7.68 (6.54–9.47)	7.42 (6.25–9.09)	0.21
Blood eosinophils
/µL	207 (119–362)	246 (138–449)	0.08
%	2.6 (1.8–4.5)	3.5 (1.8–5.4)	0.029
Blood neutrophils
/µL	4476 (3530–5506)	3890 (3157–5438)	0.016
%	58.8 (53.3–63.7)	54.3 (49.6–61.9)	0.023
Blood monocytes
/µL	482 (387–629)	520 (430–637)	0.27
%	6.4 (5.1–7.5)	7.5 (5.4–9.2)	0.046
Blood lymphocytes
/µL	2260 (1749–2612)	2382 (1955–2945)	0.27
%	28.9 (25.9–34.1)	33.0 (26.8–37.9)	0.022
Blood basophils
/µL	38 (23–51)	38 (25–42)	0.17
%	0.4 (0.4–0.7)	0.5 (0.3–0.6)	0.46
CRP, mg/L	2.9 (1.0–6.4)¶	2.0 (0.7–5.4)¶	0.14
Fibrinogen, g/L	3.5 (3.1–4.1)**	3.5 (3.0–3.7)**	0.22

*Data are presented as mean±SEM.

Data available for both visits in: †19, ‡16, §50, ¶32 and **28 patients.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts per billion.

Analysis in patients with no ICS or the same dose of ICS between two visits

In patients with no ICS (n=20) or the same dose of ICS (n=43) between two visits (table 4), there was no statistically significant change in clinical outcomes and absolute sputum and blood cells over time.

Table 4

Comparison of clinical, treatment, sputum and blood characteristics between two visits with no ICS or a stable dose of ICS

	Patients with no ICS or a stable dose of ICS, visit 1 (N=63)	Patients with no ICS or a stable dose of ICS, visit 2 (N=63)	P value
ACQ	1.7±1.1	1.7±1.2	0.91
Mini-AQLQ	4.7±1.3	4.8±1.5	0.42
Number of severe exacerbations in the previous year*	0.8±0.3†	0.7±0.3†	0.52
Prebronchodilator FEV1, % predicted	87.1±18.9	87.4±19.9	0.85
PC20M, mg/mL	2.62 (0.60–14.97)‡	2.99 (0.20->16)‡	0.94
ICS dose, beclomethasone equivalents	800 (0–2000)	800 (0–2000)	–
LABA, n (%)	42 (67)	44 (70)	0.69
LTRA, n (%)	14 (22)	15 (24)	1.0
Theophylline, n (%)	2 (3)	2 (3)	1.0
Antihistamine, n (%)	13 (21)	11 (17)	0.75
FENO, ppb	26 (14-48)§	24 (12-48)§	0.93
Sputum total non-squamous cell count, × 106/g	1.10 (0.45–2.40)	1.29 (0.43–2.53)	0.64
Sputum viability, %	66 (47–80)	63 (49–80)	0.90
Sputum squamous cells, %	15 (7–28)	16 (3–32)	0.86
Sputum eosinophils
× 103/g	18 (2–168)	36 (3–149)	0.78
% of non-squamous cells	1.6 (0.2–17.8)	1.8 (0.5–13.0)	0.53
Sputum neutrophils
× 103/g	468 (144–1954)	497 (214–1270)	0.99
% of non-squamous cells	45.0 (26.6–76.0)	61.0 (33.6–81.0)	0.041
Sputum macrophages
× 103/g	222 (122–663)	237 (74–516)	0.09
% of non-squamous cells	23.2 (13.4–46.6)	20.0 (9.8–34.0)	0.011
Sputum lymphocytes
× 103/g	11 (2–35)	10 (1–34)	0.52
% of non-squamous cells	1.2 (0.4–2.8)	0.8 (0.3–1.8)	0.17
Sputum epithelial cells
× 103/g	50 (16–95)	36 (10–96)	0.83
% of non-squamous cells	5.2 (1.6–9.8)	2.6 (1.0–9.5)	0.52
Blood leucocytes, × 109/L	7.82 (6.70–8.94)	8.03 (6.52–9.15)	0.62
Blood eosinophils
/µL	198 (132–342)	248 (120–471)	0.10
%	2.7 (1.6–4.3)	2.9 (1.6–6.8)	0.09
Blood neutrophils
/µL	4221 (3473–5177)	4380 (3540–5395)	0.80
%	55.5 (50.4–61.0)	55.9 (49.5–63.6)	0.96
Blood monocytes
/µL	568 (413–672)	543 (402–702)	0.49
%	6.9 (5.1–8.9)	6.9 (5.3–8.3)	0.91
Blood lymphocytes
/µL	2520 (2091–2900)	2404 (1932–2873)	0.28
%	31.4 (26.9–35.7)	30.1 (24.2–36.1)	0.27
Blood basophils
/µL	38 (23–53)	38 (23–53)	0.69
%	0.5 (0.3–0.6)	0.5 (0.3–0.7)	0.91
CRP, mg/L	1.5 (0.7–3.8)¶	2.4 (0.8–5.3)¶	0.33
Fibrinogen, g/L	3.6 (3.1–3.8)**	3.7 (3.3–4.4)**	0.10

*Data are presented as mean±SEM.

Data available for both visits in: †26, ‡24, §54, ¶41 and **36 patients.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts per billion.

Effect of an initiation/increased dose of ICS between two visits according to the baseline eosinophilic phenotype

After initiating (n=35) or increasing (n=44) ICS, eosinophilic asthmatics showed a significant improvement in asthma control, quality of life and FEV1 together with a reduction of bronchial hyper-responsiveness and severe exacerbations (table 5). A higher use of long-acting β2 agonists (LABA) was also concomitant with the initiation/increase of ICS. As for the sputum and blood cells, there was a decreased number of sputum eosinophils, blood eosinophils and blood lymphocytes (table 5). When excluding patients with an initiation of LABA from the analysis, there was still a statistically significant improvement (P<0.05) in ACQ (2.6±1.2 to 2.2±1.3), mini-AQLQ (4.0±1.4 to 4.3±1.5), severe exacerbation number (0.7±0.3 to 0.1±0.1), PC20M (1.03 (0.30–3.82) to 3.11 (1.14–8.25) mg/mL), FENO (60 (24–95) to 24 (14–52) parts per billion), sputum eosinophils (282 (82–992) to 113 (15–474) × 103/g and 27.0 (8.0–43.4) to 6.3 (1.3–20.4)%) and blood eosinophils (354 (217–659) to 293 (141–459))/µL). In this subgroup, there was also a marginal significance for an increase in FEV1 (76.6±18.7 to 79.7%±21.5% predicted, P=0.10) and a decrease in blood lymphocytes (2462 (2119–2949) to 2287 (1779–2948)/µL, P=0.058).

Table 5

Comparison of clinical, treatment, sputum and blood characteristics before and after an initiation/increased dose of ICS, according to the baseline eosinophilic phenotype

	Eosinophilic asthmatics before an initiation/increased dose of ICS (N=79)	Eosinophilic asthmatics after an initiation/increased dose of ICS (N=79)	P value	Non-eosinophilic asthmatics before an initiation/increased dose of ICS (N=22)	Non-eosinophilic asthmatics after an initiation/increased dose of ICS (N=22)	P value
ACQ	2.3±1.2	1.7±1.3	<0.0001	1.4±1.0	1.8±1.3	0.038
Mini-AQLQ	4.4±1.3	4.9±1.5	<0.0001	5.2±1.3	5.0±1.5	0.26
Number of severe exacerbations in the previous year*	0.8±0.3†	0.1±0.1†	0.008	0.3 ± 0.1‡	0.5 ± 0.2‡	0.32
Prebronchodilator FEV1, % predicted	76.6±17.4	81.8±17.8	0.001	87.8±21.8	81.4±26.3	0.10
PC20M, mg/mL	1.58 (0.26–3.20)§	4.91 (0.93->16)§	0.001	1.92 (0.54–10.00)¶	2.47 (0.89–10.21)¶	0.53
ICS dose, beclomethasone equivalents	400 (0–800)	1000 (800–2000)	–	400 (0–1000)	1000 (800–2000)	–
LABA, n (%)	40 (51)	72 (91)	<0.0001	11 (50)	19 (86)	0.0078
LTRA, n (%)	16 (20)	18 (23)	0.81	5 (23)	6 (27)	1.0
Theophylline, n (%)	0 (0)	0 (0)	1.0	3 (14)	3 (14)	1.0
Antihistamine, n (%)	16 (20)	17 (22)	1.0	2 (9)	2 (9)	1.0
FENO, ppb	62 (31–101)**	27 (17–50)**	<0.0001	23 (17–41)††	20 (13–64)††	0.50
Sputum total non-squamous cell count, × 106/g	1.54 (0.73–3.62)	1.43 (0.78–2.75)	0.28	0.85 (0.43–3.20)	1.96 (0.67–5.36)	0.17
Sputum viability, %	73 (54–84)	66 (55–81)	0.34	69 (52–84)	78 (55–85)	0.53
Sputum squamous cells, %	12 (5–24)	16 (6–28)	0.09	17 (5–29)	7 (2–20)	0.73
Sputum eosinophils, × 103/g	308 (113–992)	89 (10–328)	<0.0001	8 (0–18)	10 (0–45)	0.83
Sputum eosinophils, % of non-squamous cells	24.6 (7.8–43.4)	5.6 (0.8–20.4)	<0.0001	0.7 (0.0–1.6)	0.4 (0.2–3.8)	0.31
Sputum neutrophils, × 103/g	436 (176–1298)	661 (292–1506)	0.26	507 (141–2227)	1131 (262–5108)	0.25
Sputum macrophages, × 103/g	283 (98–1062)	221 (95–588)	0.16	329 (101–774)	338 (101–1088)	0.51
Sputum lymphocytes, × 103/g	25 (2–52)	13 (2–38)	0.07	13 (5–38)	16 (3–92)	0.48
Sputum epithelial cells, × 103/g	43 (15–173)	33 (7–98)	0.36	40 (10–96)	50 (8–135)	0.43
Blood leucocytes, × 109/L	7.67 (6.38–8.53)	7.59 (6.35–8.83)	0.63	7.58 (6.67–10.67)	8.10 (6.62–9.83)	0.34
Blood eosinophils, /µL	312 (203–640)	244 (141–455)	<0.0001	188 (131–258)	132 (73–229)	0.32
Blood neutrophils, /µL	3914 (3133–4689)	4044 (3403–5070)	0.14	4646 (3518–5792)	4944 (3824–5827)	0.88
Blood monocytes, /µL	513 (385–667)	569 (414–721)	0.10	510 (346–724)	538 (409–624)	0.71
Blood lymphocytes, /µL	2527 (2083–2926)	2311 (1771–2900)	0.049	2542 (2077–3090)	2440 (1756–2959)	0.19
Blood basophils, /µL	46 (23–63)	38 (21–57)	0.10	40 (31–66)	31 (22–50)	0.039
CRP, mg/L	1.7 (0.7–3.2)‡‡	1.4 (0.8–3.2)‡‡	0.61	3.8 (0.8–6.2)§§	3.7 (0.7–8.4)§§	0.88
Fibrinogen, g/L	3.4 (2.8–3.7)¶¶	3.3 (2.8–3.6)¶¶	0.93	3.1 (2.8–3.7)***	3.1 (2.7–3.4)***	0.80

*Data are presented as mean ±SEM.

Data available for both visits in: †24,‡11, §19,¶ 8, **73,††18, ‡‡57,§§12, ¶¶54, and ***10 patients.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts per billion.

In non-eosinophilic asthmatics, initiating (n=9) or increasing (n=13) ICS was associated with a worsening in ACQ (see table 6 for the effect on each question score) despite an increased usage of LABA, and overall no change in sputum and blood cells, except for a selective reduction in absolute blood basophils (table 5). When excluding patients with an initiation of LABA from the analysis, the effect on ACQ (1.7±1.0 to 2.3±1.2) and blood basophils (43 (35–78) to 31 (23–47)/µL) was still statistically significant (P<0.05).

Table 6

Detailed analysis of the score for each ACQ question before and after an initiation/increased dose of ICS in non-eosinophilic asthmatics

ACQ questions (score ranging from 0 to 6 for each question)19	Non-eosinophilic asthmatics before an initiation/increased dose of ICS (n=22)	Non-eosinophilic asthmatics after an initiation/increased dose of ICS (n=22)	P value
1. Frequency of nocturnal awakening due to asthma	0.5±1.1	1.3±1.6	0.039
2. Severity of asthma symptoms when waking	1.4±1.3	1.7±1.3	0.34
3. Limitation in activities	1.6±1.4	1.9±1.6	0.16
4. Frequency of shortness of breath	2.1±1.4	2.3±1.8	0.51
5. Frequency of wheeze	1.5±1.3	2.1±1.6	0.13
6. Frequency of short-acting β2 agonist use	0.6±0.8	1.3±1.5	0.015
7. Prebronchodilator FEV1 (% predicted)	1.9±1.8	2.3±2.2	0.27

ACQ, Asthma Control Questionnaire; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid.

Overall, the effect of an initiation/increased dose of ICS on asthma control, quality of life, exacerbation rate and FEV1 was statistically different between eosinophilic and non-eosinophilic asthmatics (figure 1).

Figure 1

Comparison of the effect of an initiation/increased dose of inhaled corticosteroid (ICS) on (A) Asthma Control Questionnaire (ACQ), (B) mini-Asthma Quality of Life Questionnaire (mini-AQLQ), (C) severe exacerbation rate and (D) forced expiratory volume in 1 s (FEV1) in eosinophilic and non-eosinophilic asthmatics. The red and blue horizontal lines represent the mean values in eosinophilic and non-eosinophilic asthmatics, respectively. EA, eosinophilic asthma; NEA, non-eosinophilic asthma.

Effect of a cessation/decreased dose of ICS between two visits according to the baseline eosinophilic phenotype

In patients with eosinophilia, withdrawing (n=5) or decreasing (n=17) the dose of ICS resulted in a worsening of asthma quality of life, together with an increase in sputum total cell count and sputum lymphocytes (table 7).

Table 7

Comparison of clinical, treatment, sputum and blood characteristics before and after a cessation/decreased dose of ICS, according to the baseline eosinophilic phenotype

	Eosinophilic asthmatics before a cessation/decreased dose of ICS (N=22)	Eosinophilic asthmatics after a cessation/decreased dose of ICS (N=22)	P value	Non-eosinophilic asthmatics before a cessation/decreased dose of ICS (N=38)	Non-eosinophilic asthmatics after a cessation/decreased dose of ICS (N=38)	P value
ACQ	2.2±1.5	2.4±1.3	0.19	1.9±1.1	1.5±1.1	0.026
Mini-AQLQ	4.4±1.8	4.1±1.6	0.045	4.3±1.3	4.9±1.4	0.007
Number of severe exacerbations in the previous year*	0.2±0.1†	0±0†	0.16	1.2±0.5‡	0.3±0.2‡	0.027
Prebronchodilator FEV1, % predicted	75.2±19.2	72.3±20.1	0.30	81.2±16.7	81.4±19.5	0.93
PC20M, mg/mL	>16 (>16->16)§	8.20 (3.35->16)§	0.17	12.00 (3.42->16)¶	3.30 (1.46->16)¶	0.19
ICS dose, beclomethasone equivalents	1800 (1000–2400)	800 (200–1600)	–	1100 (800–2000)	400 (0–1000)	–
LABA, n (%)	19 (86)	18 (82)	1.0	31 (82)	24 (63)	0.039
LTRA, n (%)	4 (18)	4 (18)	1.0	14 (37)	12 (32)	0.63
Theophylline, n (%)	0 (0)	0 (0)	1.0	1 (3)	1 (3)	1.0
Antihistamine, n (%)	4 (18)	4 (18)	1.0	7 (18)	12 (32)	0.13
FENO, ppb	48 (15–67)**	46 (25–79)**	0.59	15 (10–34)††	16 (10–30)††	0.88
Sputum total non-squamous cell count, × 106/g	1.05 (0.49–1.79)	2.03 (0.63–3.34)	0.035	1.63 (0.59–4.27)	1.16 (0.65–2.26)	0.12
Sputum viability, %	68 (61–74)	69 (52–77)	0.78	71 (63–83)	67 (59–80)	0.61
Sputum squamous cells, %	16 (9–23)	14 (2–25)	0.26	15 (3–36)	14 (4–29)	0.97
Sputum eosinophils, × 103/g	148 (28–328)	107 (24–480)	0.52	6 (0–18)	24 (2–120)	0.002
Sputum eosinophils, % of non-squamous cells	11.1 (5.4–16.3)	8.1 (1.0–24.8)	0.90	0.4 (0.0–1.4)	2.3 (0.2–6.2)	<0.0001
Sputum neutrophils, × 103/g	408 (107–823)	364 (239–1522)	0.062	685 (175–3565)	922 (242–1415)	0.50
Sputum macrophages, × 103/g	345 (112–655)	528 (110–1230)	0.24	368 (148–933)	197 (114–412)	0.026
Sputum lymphocytes, × 103/g	19 (2–59)	37 (12–94)	0.031	8 (1–50)	9 (5–39)	0.71
Sputum epithelial cells, × 103/g	59 (10–124)	112 (48–227)	0.053	53 (7–143)	25 (12–92)	0.057
Blood leucocytes, × 109/L	7.47 (6.32–9.37)	7.86 (6.74–9.49)	0.64	7.95 (6.69–9.56)	7.18 (5.81–8.87)	0.057
Blood eosinophils, /µL	319 (164–452)	304 (187–456)	0.83	179 (91–306)	218 (132–441)	0.032
Blood neutrophils, /µL	4209 (3666–5303)	3953 (3526–4927)	0.71	4684 (3500–5774)	3785 (2882–5606)	0.007
Blood monocytes, /µL	452 (354–645)	517 (381–692)	0.37	498 (407–626)	526 (452–610)	0.55
Blood lymphocyte, /µL	2383 (1979–2624)	2628 (2288–2957)	0.37	2220 (1729–2600)	2188 (1948–2914)	0.49
Blood basophils, /µL	42 (28–56)	38 (32–42)	0.19	33 (23–47)	35 (23–43)	0.44
CRP, mg/L	1.8 (1.1–3.7)‡‡	1.8 (0.5–3.6)‡‡	0.50	3.2 (0.9–8.4)§§	2.2 (0.8–5.9)§§	0.18
Fibrinogen, g/L	3.3 (3.0–3.5)¶¶	3.4 (3.0–3.7)¶¶	0.65	3.9 (3.3–4.2)***	3.5 (3.0–3.8)***	0.07

*Data are presented as mean±SEM.

Data available for both visits in: †9, ‡10, §3,¶13, **19,††31 ‡‡11, §§21, ¶¶10, and ***18 patients.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts per billion.

In non-eosinophilic asthmatics, withdrawing (n=13) or decreasing (n=25) the dose of ICS was associated with an improvement in asthma control and asthma quality of life as well as a reduction in the rate of severe exacerbations, despite a decreased usage of LABA (table 7). They also showed an increased number of sputum and blood eosinophils and a decreased number of sputum macrophages and blood neutrophils (table 7). When excluding patients with a cessation of LABA from the analysis, there was still a statistically significant effect (P<0.05) on ACQ (1.8±1.1 to 1.4±1.0), mini-AQLQ (4.6±1.3 to 5.1±1.3), severe exacerbation number (1.1±0.5 to 0.4±0.3), sputum eosinophils (9 (0–18) to 42 (9–128) × 103/g and 0.4 (0.0–1.8) to 2.8 (0.8–12.6)%), sputum macrophages (410 (148–933) to 219 (120–412) × 103/g), blood eosinophils (188 (91–306) to 258 (148–453)/µL) and blood neutrophils (4816 (3414–5774) to 3785 (2811–5419)/µL).

Overall, the effect of a cessation/decreased dose of ICS on asthma control and asthma quality of life was statistically different between eosinophilic and non-eosinophilic asthmatics (figure 2).

Figure 2

Comparison of the effect of a cessation/decreased dose of inhaled corticosteroid (ICS) on (A) Asthma Control Questionnaire (ACQ), (B) mini-Asthma Quality of Life Questionnaire (mini-AQLQ), (C) severe exacerbation rate and (D) forced expiratory volume in 1 s (FEV1) in eosinophilic and non-eosinophilic asthmatics. The red and blue horizontal lines represent the mean values in eosinophilic and non-eosinophilic asthmatics, respectively. EA, eosinophilic asthma; NEA, non-eosinophilic asthma.

Discussion

To the best of our knowledge, our data are the first to provide evidence of effectiveness of ICS on airway and blood inflammation in real life. Initiating or increasing ICS in asthmatics sharply reduces sputum eosinophils and to a lesser extent blood eosinophils. Our data also show that effectiveness of ICS in reducing symptoms, improving quality of life and lung function and decreasing exacerbations is essentially observed in the eosinophilic asthma phenotype. On the other hand, our data suggest that stepping-down ICS in non-eosinophilic asthma may actually improve symptoms and quality of life and even reduce the exacerbation rate.

We provide here convincing evidence that ICS are powerful drugs to reduce airway eosinophilic inflammation in clinical practice. As previously shown,6 11 we found that initiating/increasing the dose of ICS resulted in a greater decrease in sputum than in blood eosinophils. Whether this effect on blood eosinophils reflects a systemic action of ICS (by absorption through the lungs and gastrointestinal tract)25 or is a consequence of the local inhibition of IL-5 production/release26 remains to be elucidated. Whichever the reason, our results clearly show the preferential effect of ICS on the airway compartment. As opposed to what was observed after initiating/increasing the dose, a cessation/reduction in the dose of ICS resulted in an increase in sputum eosinophils, which is consistent with previous studies.8 9 At the systemic level, we noticed a significant reduction in the amount of circulating blood neutrophils when decreasing the dose of ICS, maybe explained by the inhibitory effect of corticosteroids on neutrophil adhesion to endothelial cells.27 The lack of change in absolute sputum and circulating cells in the group of patients not receiving ICS or keeping the same dose of ICS between two visits (the control group) further supports the role of ICS in the changes found in the two preceding groups.

It is worth noting that neither the increase nor the decrease of ICS had an impact on markers of systemic inflammation like CRP or fibrinogen. This contrasts what has been shown in some28 29 but not all30 studies in which ICS were suggested to reduce the CRP levels in patients with chronic obstructive pulmonary disease (COPD). This might be explained by the fact that CRP levels are higher in patients with COPD as compared with asthmatics, thereby leaving room for a decrease with a drug intervention. In patients with asthma, Takemura et al found that corticosteroid-naive, but not corticosteroid-treated asthmatics had higher CRP levels than control subjects,31 but evidence from longitudinal studies is lacking.

A strength of our study is that our data further highlight the importance of baseline eosinophilic phenotype in the response to ICS.10 14 Initiating or increasing the dose of ICS essentially provides clinical benefit in patients with baseline sputum eosinophils≥3%. In this group of patients, we observed a clear improvement in asthma control, asthma quality of life, baseline airway calibre as well as a reduction in bronchial hyper-responsiveness. Furthermore, there was also a marked reduction in the number of severe exacerbations recorded in the year prior to the visit. The average improvement in ACQ and mini-AQLQ reached at least 0.5, which is the individual minimal important difference accepted for these questionnaires.20 32 Likewise, the improvement in bronchial hyper-responsiveness was above one doubling dilution, which is generally considered as clinically relevant.21 The mean annual rate of severe exacerbations fell from 0.8 to 0.1 per patient, yielding an 88% reduction. These results are consistent with previous studies showing that adjusting treatment with ICS to normalise the sputum eosinophil count resulted in a decrease in severe asthma exacerbations33 34 and with the fact that asthma control fluctuates with sputum eosinophils over time.23 We believe that sputum eosinophils are both a predictor of response to ICS and a therapeutic target of ICS.35 Contrasting with the clear effects observed in eosinophilic asthmatics, patients with a sputum eosinophil count less than 3% at baseline did not show any clinical benefit of an initiation or an increase in the dose of ICS, and there was even a hint for a symptomatic deterioration of patients as there was a significant increase in ACQ between the two visits (accounted for by a raised frequency of nocturnal awakening due to asthma and an increased reliever use). This would suggest that it is useless to decide for a rise in ICS dosage in uncontrolled non-eosinophilic asthmatics. Therefore, these results emphasise the importance to assess the level of airway eosinophilic inflammation in clinical practice before treating patients with ICS, in order to reduce as much as possible inappropriate treatment with corticosteroids.36 37

Our study also demonstrates that decreasing the dose of ICS in non-eosinophilic asthmatics may actually result in an improvement in asthma control and quality of life, maybe partly linked to the reduction of local side effects of ICS, like cough, pharyngitis or dysphonia.38 Surprisingly, there was also a reduction in exacerbation rate, although this should be taken with caution because of the limited number of subjects in whom the parameter was assessed (n=10). These results are consistent with the finding of Green et al showing in a subgroup analysis that it was possible to reduce the dose of ICS in non-eosinophilic asthmatics without any deterioration in asthma control.33 In eosinophilic asthmatics, a reduction of ICS did not result in a dramatic rise in eosinophilic inflammation. Similarly, apart from a mild deterioration in quality of life, there was no impact of the ICS reduction on asthma control, baseline airway calibre and exacerbation rate. This might be explained by the fact that most patients in whom ICS were stepped down had a high dosage at baseline and were kept on a low-to-medium dose of ICS after the reduction, at which most of the benefits occur.39

Determining the eosinophilic or non-eosinophilic phenotype is not widely available in clinical practice because the technique of induced sputum is technically demanding and time-consuming. While its implementation may be possible in secondary care centres, we acknowledge that it would be impracticable in primary care centres. However, when the technique of induced sputum is not available, several user-friendly surrogate markers might be used to predict the presence or absence of sputum eosinophilia, like FENO, blood eosinophils and total serum IgE.40 Moreover, it would be worth investigating in large real-life studies the ability of those biomarkers to predict response to ICS by comparison with sputum eosinophils.

Being retrospective, our study has several limitations. Due to the variation in the delay between both visits and to the unknown adherence to treatment, the cumulative dose of ICS received by the patients before the investigation remains uncertain. A second limitation of our study is the fact that ICS were not the only drugs to be changed between both visits, as in the large majority of patients, ICS were combined with LABA which may also impact clinical outcomes. However, the fact that most results remained statistically significant when patients with variations in LABA use were excluded from the analysis enhances confidence in the findings. A third limitation of our study is that the reason why the dose of ICS was changed between both visits may be plural: it can either be related to a recommended strategic treatment choice by the chest physician or the general practitioner, or linked to a loose adherence of patients to their treatment plan. Finally, we did not perform any formal sample size calculation in our study and we therefore acknowledge that the statistical power may be insufficient for several comparisons in our results.

To conclude, our results confirm the effectiveness of ICS on eosinophilic inflammation in real life and demonstrate the clinical benefit of initiating or raising the dose of ICS in eosinophilic asthma, but cast doubt on the clinical utility of stepping-up ICS in non-eosinophilic asthma. Our data also suggest that high dose of ICS can be safely stepped down in non-eosinophilic asthmatics. Overall, we believe that the benefits of ICS in non-eosinophilic asthmatics should be clarified in long-term prospective trials.